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Diagnostic Utility of Genome-wide DNA Methylation
Testing in Genetically Unsolved Individuals
with Suspected Hereditary Conditions
Erfan Aref-Eshghi,1,2 Eric G. Bend,3 Samantha Colaiacovo,4 Michelle Caudle,4 Rana Chakrabarti,4
Melanie Napier,4 Lauren Brick,5 Lauren Brady,5 Deanna Alexis Carere,2 Michael A. Levy,1,2
Jennifer Kerkhof,2 Alan Stuart,2 Maha Saleh,4 Arthur L. Beaudet,6 Chumei Li,5 Maryia Kozenko,5
Natalya Karp,4 Chitra Prasad,4 Victoria Mok Siu,4 Mark A. Tarnopolsky,5 Peter J. Ainsworth,1,2
Hanxin Lin,1,2 David I. Rodenhiser,7 Ian D. Krantz,8 Matthew A. Deardorff,8 Charles E. Schwartz,3
and Bekim Sadikovic1,2,*
Conventional genetic testing of individuals with neurodevelopmental presentations and congenital anomalies (ND/CAs), i.e., the anal-
ysis of sequence and copy number variants, leaves a substantial proportion of them unexplained. Some of these cases have been shown
to result from DNA methylation defects at a single locus (epi-variants), while others can exhibit syndrome-specific DNA methylation
changes across multiple loci (epi-signatures). Here, we investigate the clinical diagnostic utility of genome-wide DNAmethylation anal-
ysis of peripheral blood in unresolved ND/CAs. We generate a computational model enabling concurrent detection of 14 syndromes
using DNA methylation data with full accuracy. We demonstrate the ability of this model in resolving 67 individuals with uncertain
clinical diagnoses, some of whomhad variants of unknown clinical significance (VUS) in the related genes.We show that the provisional
diagnoses can be ruled out in many of the case subjects, some of whom are shown by our model to have other diseases initially not
considered. By applying this model to a cohort of 965 ND/CA-affected subjects without a previous diagnostic assumption and a separate
assessment of rare epi-variants in this cohort, we identify 15 case subjects with syndromic Mendelian disorders, 12 case subjects with
imprinting and trinucleotide repeat expansion disorders, as well as 106 case subjects with rare epi-variants, a portion of which involved
genes clinically or functionally linked to the subjects’ phenotypes. This study demonstrates that genomic DNAmethylation analysis can
facilitate the molecular diagnosis of unresolved clinical cases and highlights the potential value of epigenomic testing in the routine
clinical assessment of ND/CAs.
Introduction
Constitutional disorders that present with developmental
delay (DD), intellectual disability (ID), and/or congenital
anomalies (CA) are associated with variable, complex,
and overlapping clinical features. Current methodologies
for the screening and diagnosis of neurodevelopmental
syndromes with or without congenital anomalies (ND/
CA) involve clinical microarray testing for detection of
copy number variants (CNVs),1 along with targeted gene
panel and exome sequencing to identify rare pathogenic
sequence variants.2 Despite exhaustive assessments, in a
large proportion of case subjects, the underlying genetic
etiology is not identified or the clinical assessment does
not indicate a diagnosis.3 This is in part due to the inade-
quate assessment of non-coding and more complex
sequence variants (e.g., long indels) through conventional
approaches,4 as well as limited knowledge of the genetic
etiology of many clinically defined conditions. Further-
more, a large proportion of the genetic changes identified
through genetic testing in a potentially relevant gene are
not clinically interpretable, i.e., variants of unknown clin-
ical significance (VUS).
One critical aspect of the molecular etiology of ND/CA
that is not currently screened for in the clinical settings in-
volves heritable changes that do not entail alterations in
the DNA sequence, also known as epigenetics.5 Defects
in DNA methylation, the most commonly studied epige-
netic phenomena, have long been known to be involved
in a certain group of constitutional syndromes such as
imprinting conditions and trinucleotide repeat expansion
disorders.6,7 Epi-variants, a class of genetic variants that
involve a change in the DNA methylation patterns of a
limited number of CpGs at a specific locus, have recently
been proposed as a potential contributor to hereditary con-
ditions.8,9 It has been observed that rare de novo epi-vari-
ants are found at a higher frequency in unexplained ND/
CA-affected case subjects, and their impact on gene expres-
sion has been shown to be comparable to those involving
loss-of-function sequence variants, providing a rationale
that some of these epi-variants may contribute to the
pathogenesis of some of the unexplained ND/CAs.9 On
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the other hand, we and others have shown that many ge-
netic syndromes exhibit unique combinations of DNA
methylation changes at multiple loci across the genome,
i.e., epi-signatures, which can be used to resolve ambig-
uous clinical cases and classify those carrying VUSs in rele-
vant genes.10–14 Since both epi-variants and epi-signatures
reflect a fundamental defect, they are detectable to variable
extents across multiple tissues, including peripheral blood,
which is easily accessible and remains a common source of
clinical diagnostic specimens.9,15
In the present study, using genome-wide DNA methyl-
ation analysis, we develop a computational model for
the concurrent identification of 14 ND/CA syndromes
currently known to be associated with an epi-signature.
Using this model, we demonstrate the ability to resolve
67 subjects with uncertain clinical diagnoses, some of
whom had VUSs in clinically relevant genes. We show
that the provisional diagnoses can be ruled out for most
of these subjects, a few of whom are shown by our model
to have other diseases initially not considered. Application
of this model to a cohort of 965 ND/CA-affected case
subjects with no diagnosis despite a previously extensive
genetic work-up enables the identification of 15 case sub-
jects with one of the above syndromes. We also identify
12 individuals with imprinting and trinucleotide repeat
expansion disorders, as well as 106 individuals with rare
epi-variants, a subset of which occurs at genes with a clin-
ical/functional link to the subjects’ phenotypes.
Subjects and Methods
Subjects and Cohorts
To design a computational model for the detection of congenital
syndromes, peripheral blood DNA samples from subjects diag-
nosed with 14 syndromes known to date to harbor a DNAmethyl-
ation epi-signature in the blood were collected. These included
individuals with autosomal-dominant cerebellar ataxia with deaf-
ness and narcolepsy (ADCADN [MIM: 604121]), ATRX syndrome
(MIM: 300032), BAFopathies (Coffin-Siris [MIM: 614607, 135900,
618027, 617808, 616938, 614609, and 614608], Nicolaides-Bar-
aitser [MIM: 601358], andChr6q25del [MIM: 612863] syndromes),
CHARGE syndrome (MIM: 214800), Claes-Jensen syndrome (MIM:
300534), genitopatellar syndrome (GTPTS [MIM: 606170]),
Floating-Harbor syndrome (FHS [MIM: 136140]), Kabuki syndrome
(MIM: 147920), and Sotos syndrome (MIM: 117550), all of which
were described in our previous studies10,11,13,14,16–18 andwere orig-
inally recruited from the Greenwood Genetic Center (Greenwood,
SC, USA), Care4Rare Canada Consortium (Ottawa, ON, Canada),
and London Health Sciences Center (London, ON, Canada). To
this cohort, we added subjects with Down syndrome (MIM:
190685), Cornelia de Lange syndrome (CdLS [MIM: 122470,
614701, 610759, 300590, and 300882]), and ADNP syndrome
(MIM: 615873), which were not previously published, obtained
from McMaster University Medical Centre (Hamilton, ON, Can-
ada) and Greenwood Genetic Center. Samples with Williams
syndrome (MIM: 194050) and Chr7q11.23 duplication (Dup7
[MIM: 609757]) syndromes were downloaded from gene expres-
sion omnibus (GEO: GSE66552).15,19We supplemented the cohort
of subjects with CHARGE syndrome, Sotos syndrome, Kabuki
syndrome, and Down syndrome with publicly available DNA
methylation data from GEO (GSE74432, GSE97362, GSE116300,
GSE52588).11,15,20,21
Samples from other ND/CA disorders which were used only to
measure the specificity of the classification model designed later,
including those with Angelman syndrome (MIM: 105830),
Prader-Willi syndrome (MIM: 176270), Beckwith-Wiedemann
syndrome (MIM: 130650), Coffin-Lowry syndrome (MIM:
303600), Rett syndrome (MIM: 312750), Saethre-Chotzen syn-
drome (MIM: 101400), Fragile X syndrome (MIM: 300624), autism
spectrum disorders, and RASopathies, were described by our previ-
ous studies6,7,11,13,14 which were collectively obtained from the
Greenwood Genetic Center. DNAmethylation data files from sub-
jects with Silver-Russell syndrome (MIM: 180860) andWeaver syn-
drome (MIM: 277590) were obtained from GEO (GSE104451,
GSE55491, GSE74432).22,23
Any subject used herein to represent a genetic condition had a
confirmed clinical diagnosis of the aforementioned syndrome
andwas screened formutations in the related genes. Themutation
report for every subject was reviewed according to the American
College of Medical Genetics (ACMG) guidelines for interpretation
of genomic sequence variants,24 and only individuals confirmed
to carry a pathogenic or likely pathogenic mutation and to have
the clinical diagnoses were used to represent a syndrome.
Controls comprised healthy subjects with no developmental
delay, intellectual disability, or congenital anomalies. The first
set of controls that were used for feature selection and model
training was collected from the Greenwood Genetic Center, the
reference cohort in the LHSC laboratory, and two publicly avail-
able databases of healthy pediatric cohorts (GEO: GSE104812,
GSE97362).21,25 Control subjects that were later added to measure
the specificity of our classifier and to map the rare DNA methyl-
ation epi-variants were compiled from five large databases of
general population samples with various age distributions and
racial backgrounds (GEO: GSE42861, GSE85210, GSE87571,
GSE87648, and GSE99863).26–29
Samples with uncertain diagnoses as well as unsolved case
subjects that were screened in this study for the detection of
potentially affected individuals were collected from all of the sour-
ces above over a period of 4 years. These samples were supple-
mented with publicly available DNA methylation files from
GEO for case subjects suspected to have Kabuki syndrome (GEO:
GSE116300)20 as well as a cohort of unsolved ND/CA-affected sub-
jects (GEO: GSE89353).9
Methylation Experiment and Quality Controls
Peripheral whole-blood DNA was extracted using standard tech-
niques. Following bisulfite conversion, DNA methylation analysis
of the samples was performed using the Illumina Infiniummethyl-
ation 450k or EPIC bead chip arrays, according to the manufac-
turer’s protocol. This array covers above 860,000 human genomic
methylation CpG sites, including 99% of RefSeq genes, all of the
known disease-associated imprinted loci in humans, and 96% of
CpG islands. The resulting methylated and unmethylated signal
intensity data were imported into R 3.5.1 for analysis. Normaliza-
tion was performed according to the Illumina normalization
method with background correction using the minfi package.30
Probes with detection p values > 0.01, those located on chromo-
somes X and Y, those known to contain a SNP at the CpG
interrogation or single nucleotide extension, and probes known
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to cross-react with chromosomal locations other than their target
regions were removed. Arrays with more than 5% failure probe
rates were excluded from the analysis. All of the samples were
examined for genome-wide methylation density, and those devi-
ating from a bimodal distribution were excluded. Factor analysis
using a principal component analysis (PCA) was performed to
examine the batch effect and identify the outliers. Since samples
were assayed using two different platforms (450k and EPIC), after
normalization and quality controls the downstream analyses were
restricted to the probes shared across the two array types to main-
tain consistency in the computational workflow.
Selection of Case Subjects and Matched Control
Subjects
We selected a random 75% subset of all case subjects with syn-
dromes known to have DNA methylation epi-signatures as a
training cohort for the purpose of feature selection and model
training. The remaining 25% was set aside as a testing dataset to
be used for the assessment of the performance of the classification
model developed later. It was ensured that all of the syndromes and
subtypes are equally represented in both of the training and testing
cohorts. No division to training/testing cohort was performed for
conditions with low sample sizes including ADCADN (n ¼ 5) and
genitopatellar syndrome (n ¼ 3), and the samples from these dis-
eases were only used for training. For every syndrome in the
training cohort, an age-matched group of control subjects was
selected using the MatchIt package. In the case of BAFopathies
and CHARGE syndrome, in which the samples were processed us-
ing two different platforms (450k and EPIC), control subjects
were also matched to the case subjects by the array type to avoid
any experimental bias during the feature selection. The sample
size of the controls was increased until both the matching quality
and sample sizewere at their optimumand consistent across all dis-
eases. This led to the determination of a control sample size four
times larger than the case group in every comparison. Increasing
the sample size beyond this value impaired the matching quality.
After every matching trial, a PCA was performed to detect outliers
and examine the data structures. Outlier samples and those with
aberrant data structures were removed before a second matching
trial was conducted. The iteration was repeated until no outlier
sample was detected in the first two components of the PCA.
Feature Selection for Model Training
The analysis was performed according to our previously published
protocol.11,13,14,31 The methylation level for each probe was
measured as a beta value, calculated from the ratio of the methyl-
ated signal intensity versus the total sum of unmethylated and
methylated signal intensities for that probe, ranging between
0 (no methylation) and 1 (full methylation). Feature selection
was performed in two steps separately for every disease. First, a
multivariate limma regressionmodeling32 was conducted to prior-
itize thedifferentiallymethylatedprobes thatwerenot confounded
by blood cell type compositions. The estimation of blood cell
mixture was performed according to the algorithm developed by
Houseman et al.33 The estimated values for each cell component
were incorporated into themodel matrix of the regression analysis
as confounding variables. The analysis was restricted to probes
showing a minimum methylation difference between the case
subjects and control subjects. This valuewas determined separately
for each condition since every disease is associated with a different
effect size in methylation change. Using the examination of the
volcano plots of the regressionmodeling, this effect size was deter-
mined to be 5% for BAFopathies, CdLS, and CHARGE syndromes,
15% for Down syndrome, ADNP syndrome, ATRX syndrome, Wil-
liams syndrome, andDup7, 20% forGTPTS andADCADN, 25% for
Sotos syndrome, and 10% for others. No probe with less than 5%
methylation difference was used since microarray technology is
not sensitive enough in detecting this level of variation in DNA
methylation. For linear regression modeling, beta values were
logit transformed to M-values using the following equation: log2
(beta/(1  beta)). The obtained p values were moderated using
the eBayes function. TheCpGswere sorted according to themoder-
ated p values (ascending), and the top 1,000 were retained for
feature selection. In the second step, we performed a receiver’s
operating curve characteristics analysis for every probe and identi-
fied those with an area under the curve (AUC) > 0.80. Finally, we
measured the pairwise correlations across the probes and removed
the highly correlated features with R-squared > 0.80.
Clustering and Dimension Reduction
The selected probes were examined using a hierarchical clustering
analysis to ensure their ability in separating the case subjects from
control subjects and to examine the similarity between various
subtypes of the studied disorders. Hierarchical clustering was per-
formed using Ward’s method on Euclidean distance by the gplots
package. A dimension reduction on the combination of the probes
identified in each comparison was performed using t-distributed
stochastic neighbor embedding (t-SNE) to examine the degree of
overlap across different syndromes. The analysis was performed
using the Rtsne package according to the default parameters to
reduce the dimensions of the data to two.34 Different values for
the t-SNE perplexity parameter were explored to ensure the consis-
tency of the findings. No change in the outcome was observed at
different trials; therefore, the default perplexity parameter in the
Rtsne package (perplexity ¼ 30) was used for the results presented
in the manuscript.
Construction of a Multi-class Prediction Model
To design a classificationmodel for the concurrent detection of the
syndromes, amulticlass support vector machine (SVM) with linear
kernel was trained on the training dataset using all of the selected
probes. Training was done using the e1071 R package. Every dis-
ease was used in the training as a distinct class, except for
BAFopathies in which the clustering analysis indicated that they
may not be completely differentiated from each other. Healthy
control subjects were considered as an additional class. To deter-
mine the best hyperparameter used in linear SVM (cost), and to
measure the accuracy of the model, 10-fold cross-validation was
performed during the training. In this process, the training set
was randomly divided into ten folds. Nine folds were used for
training the model and one fold for testing. After repeating this
iteration for all of the ten folds, the mean accuracy was calculated,
and the hyperparameters with the optimal performance were
selected. For every sample, the model was set to generate multiple
scores ranging from 0 to 1, representing the confidence of predic-
tion for each class. Conversion of SVM decision values to these
scores was done according to the Platt’s scaling method.35 The
final model was applied to the testing dataset to ensure the success
of the training. The class receiving the greatest score determined
the predicted phenotype. Samples with diseases other than those
used in the training are expected to be classified as control
subjects.
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Validation of the Classification Model
Weensured that the constructedmodel is not sensitive to the batch
structure of themethylation experiment by applying it to all of the
samples assayed on the same batch as the cases in the training data-
set. To confirm that the classifier is not sensitive to the blood cell
type compositions,wedownloadedmethylationdata from isolated
blood cell populations of healthy individuals from GEO
(GSE35069)36 and supplied them to our model for prediction and
examined the degree to which the resulting scores were varied
across different blood cell types. Next, the model was applied to
the testing cohort (25% subset of the affected case subjects not
used for feature selectionor training) to evaluate thepredictive abil-
ity of themodel on affected subjects. To determine the specificity of
the model, we supplied a large number of DNAmethylation arrays
from healthy subjects to the model. To understand whether this
model was sensitive to other medical conditions presenting with
ND/CA,we tested a large number of subjects with a confirmed clin-
ical and molecular diagnosis of such syndromes by the model.
Screening of Undiagnosed and Uncertain Cases
The final model was used to classify subjects suspected of having
any of the conditions used in the training including those with
no sequence variant information available, with inconclusive clin-
ical assessment, or with VUS. In addition, we used the model to
screen a large group of individuals with various presentations of
ND/CA but no established diagnosis despite udergoing routine
clinical and molecular assessments including microarray CNV
testing or exome sequencing. The subjects that were predicted as
having any of the syndromes above were evaluated based on the
available clinical and molecular information.
Exome Sequencing and Structural Variant Detection
Subjects with no mutation report, predicted herein to have a
defined syndrome, were sequenced using a custom designed
next-generation sequencing panel developed using SeqCap EZ
MedExome probes covering the coding sequences of 4,600
genes. These genes are identified to be medically relevant by the
consortium of the Emory Genetics Lab, Harvard Laboratory of Mo-
lecular Medicine, and Children’s Hospital of Philadelphia. The raw
sequence data files (FASTQ) were mapped to the GRCh37 (hg19)
reference sequence using Burrows-Wheeler aligner with default
parameters.37 The sorted and indexed binary alignment map
(BAM) files were used by VarDict for calling single-nucleotide var-
iants and small to moderate size indels.38 Detection of large dele-
tions, duplications, and insertions was performed using Pindel.39
Copy number changes in the size of an exon and above were
investigated using the ExomeDepth algorithm,40 which is shown
to have outstanding performance in the detection of rare CNVs
involved in Mendelian disorders.41 Variant annotation was per-
formed using Alamut Batch v.1.5.2 (Interactive Biosoftware). To
rule out that the identified individuals do not have other condi-
tions explaining their clinical presentations, we did not limit the
analysis to the disease candidate genes and evaluated the entire
set of the 4,600 genes for a potentially causative variant.
Identification of Rare DNA Methylation Epi-variants
Individuals for whom the conducted analyses did not propose a
potential syndrome were screened for a single high-penetrant
DNA methylation defect at a single locus with an outlier DNA
methylation pattern as compared with a large cohort of controls
(epi-variant). First,weused abump-hunting approachby thebump-
hunter package42 to identify regionswithR3consecutiveprobesno
more than 500 bp apart with a minimum average regional methyl-
ation difference of 0.1 between the case subject and the control
subjects. Detection of regions on X and Y chromosomes was
performed separately using control subjects of the same sex as
each case subject. For every identified region, we measured an
average ratio of between-group variance to within-group variance
(F-statistic). A higher F-statistic indicates a greater deviation of the
regional methylation level in the screened individual from a more
tightlymethylated region in control subjects. Regionswith anF-sta-
tistic < 20 were excluded. From the remaining regions, those with
either an F-statistic > 40 or with a methylation difference > 0.2
were retained.Next,weplotted themethylation levels in every indi-
vidual against all of the control subjects for each prioritized region.
Followingamanual reviewof theplots,we selected regions showing
an outlier pattern that was completely absent or found in%5 of the
control subjects. The final list of regions was annotated to genes
within 5 kb of the region, gene promoters (defined as 5 kb upstream
to 1 kb downstream the transcription start site), andCpG islands, as
well as to the OMIM gene and phenotype identifiers. Annotation
was performed using the Bioconductor package AnnotationHub
(seeWebResources).Using thegeneimprint database,we annotated
our gene list for an overlap with the known imprinted loci in the
Homo sapiens. A comprehensive literature search was then per-
formed for every region to identify those with a potential involve-
ment in the clinical presentations of the unresolved individuals.
Technical Validation of Epi-variants
To ensure that the outlier methylation patterns in the identified re-
gions are not due to experimental problems, several of the regions
were subject to technical validation using either a repeatmicroarray
experimentof anotherplatform(EPICversus450k arrays) or bisulfite
sequencing. The latter was performed using NimbleGen SeqCap Epi
Target Enrichment probes, custom designed to cover the candidate
regions and their 1 kb flanking. The raw sequence data files (FASTQ)
were mapped to the GRCh37 (hg19) reference sequence using
BSMAP mapper,43 followed by the trimming of the adaptor se-
quences. Duplicate sequences were removed, the BAM files were
filtered forproperlypairedreads,and theoverlapping readswereclip-
ped. BSMAPwas then used to estimate a methylation ratio for every
CpG dinucleotide in the target regions. None of the regions selected
to be used in this experiment failed the confirmation, indicating the
accuracy of microarray in the detection of epi-variants.
Ethics Statement
The study protocol has been approved by the Western University
Research Ethics Board (REB 106302), McMaster University, and the
Hamilton Integrated Research Ethics Boards (REB 13-653-T). All of
the participants provided informed consent prior to sample collec-
tion. All of the samples and records were de-identified before any
experimental or analytical procedures. The research was conduct-
ed in accordance with all relevant ethical regulations.
Results
Development of a Computational Model for Concurrent
Classification of Constitutional Syndromes using
Genome-wide DNA Methylation Data
We compiled peripheral blood DNA methylation data,
generated using Infinium methylation arrays for 383
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subjects who had confirmed clinical and molecular diagno-
ses of 14 syndromes with previously described epi-signa-
tures, including ADCADN, ADNP, ATRX, BAFopathies,
CHARGE, CJS, CdLS, Down, Dup7, FHS, GTPTS, Kabuki, So-
tos, and Williams syndromes (Table S1). Following quality
controls, 400k probes (CpG sites) were retained for anal-
ysis in each condition. The entire cohort of the affected sub-
jects was randomly divided into two sets of training (75%
subset, n ¼ 287) and testing (the remaining 25%, n ¼ 96),
ensuring every disease/subtype was equally represented in
both subsets. For each disease group in the training cohort,
an age-matched cohort of control subjects with a sample
size four times larger was selected from a pool of healthy
control subjects (n ¼ 565) for the purpose of feature selec-
tion andmodel training. Usingmoderated p values adjusted
for blood cell type compositions (limmamultivariate regres-
sion modeling), we initially prioritized the top 1,000 differ-
entially methylated probes. Subsequently, this list was
narrowed down to the most differentiating features (area
under the receiver operating characteristic curve > 0.8)
followed by the removal of the redundant probes (pairwise
correlation coefficient > 0.8). Hierarchical clustering of the
final probes in each disease confirmed that they completely
separated the case subjects from control subjects in most of
the situations. The only exceptions were noticed for ADNP
syndrome and BAFopathies. In ADNP syndrome, subjects
with mutations between c.2000 and c.2340 (11 of 23
ADNP-affected case subjects; Table S1) generated an oppo-
site pattern to the rest; whereas in BAFopathies, different
subtypes showed overlapping DNA methylation patterns.
Thus, subjects with BAFopathies were treated as a single
entity, while those with ADNP were divided into two
distinct categories (ADNP-1 [those with mutations in the
entire ADNP gene (MIM: 611386) outside c.2000–2340]
and ADNP-2 [those with mutations in ADNP between
c.2000 and c.2340]). Feature selection for these 15 categories
retained on average 50 probes per condition, the intersec-
tions between which were negligible (Table S2). Dimension
reduction on the methylation data of all of these probes
(n ¼ 856, Table S2) using t-SNE demonstrated that each dis-
order was distinct from the others (Figure 1). The addition of
the testing subset to this analysis revealed that every testing
sample clustered with members of the same class and did
not mix with others (Figure 1). This indicated that the
selected probes were robust in the differentiation of the
syndromes, both from each other as well as from control
subjects, and thus, it would be possible to generate one
model for concurrent classification of all of the syndromes.
We trained a multi-class support vector machine (SVM),
composed of 16 classes (15 disease and 1 control categories),
using all of the prioritized probes (n ¼ 856) and samples in
the training set (287 affected case subjects and 565 healthy
control subjects). For every subject, the model was set to
generate 16 scores ranging 0–1, representing the confidence
in predicting whether they have a DNAmethylation profile
similar to each of the 16 classes in the model. The class
obtaining the greatest score determined the predicted
phenotype of a subject. 10-fold cross-validation during the
training process resulted in an average accuracy of 99.3%
(model details in Table S3).
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Figure 1. Dimension Reduction of
DNA Methylation Data in Constitutional
Syndromes
Using t-distributed stochastic neighbor
embedding (t-SNE), we reduced the
dimension of the DNA methylation data
of all of the prioritized features (856
CpGs) in all of the individuals with the
constitutional syndromes in the study.
The data were reduced to two dimensions
as presented on the x and y axes. Every
point represents one subject. Subjects in
the training cohort who were used for
feature selection are shown in lighter
colors, and those from the testing cohort
who were not used for the prioritization
of features are shown in darker colors.
The plot shows that every disease gener-
ates a distinct cluster from the others
and the samples in the testing cohort
cluster within the correct disease group.
BAFopathies, regardless of the subtype,
generate one cluster, while those with
ADNP syndrome, depending on the muta-
tion coordinates, generate two distinct
groups (ADNP-1andADNP-2).Theobserved
pattern could not be explained by the
experimental batch structure of the data.
Abbreviations:CdLS,Cornelia deLangesyn-
drome; CJS, Claes-Jensen syndrome; FHS,
Floating-Harbor syndrome; GTPTS, genito-
patellar syndrome.
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To control for the success of the procedure, the entire
training cohort was supplied to the final model, which as-
signed correct classifications to all of the case and control
subjects used for training (Figure 2). Every sample was clas-
sified into the category it belonged to, with scores signifi-
cantly greater from the others.Wewere also able to confirm
that the model was not sensitive to the batch structure of
the data by applying it to other samples processed on the
same batch as the case subjects, all of which were classified
as control. Additionally, we evaluated the extent to which
this model was sensitive to variations in blood cell type
compositions by applying it to a total of 60 methylation
array data files from 6 healthy individuals, each being as-
sayed separately for whole blood, peripheral blood mono-
nuclear cells, and granulocytes, as well as for 7 isolated
cell populations (CD4þ T, CD8þ T, CD56þ NK, CD19þ B,
CD14þ monocytes, neutrophils, and eosinophils). All of
these samples were classified as controls with <5% average
inter-cell-type variability in the scores (Table S4).
We next applied the model to the entire testing cohort,
composed of 96 samples that were not used for feature
selection or model training. All of these samples were as-
signed the expected class with scores similar to those of
the training dataset, confirming that the model was robust
in the classification of the 16 categories (Figure 2). To mea-
sure the specificity of our classifier, we tested a total of
2,315 whole-bloodmethylation data fromhealthy subjects
of various racial backgrounds (aged 0–94 years) obtained
from GEO (GSE42861, GSE85210, GSE87571, GSE87648,
and GSE99863), all of which were confidently classified
as control (Figure 2). We also questioned whether the
model could differentiate the above syndromes from other
congenital or Mendelian disorders not included in the
training. DNA methylation profiles of a total of 442 sub-
jects diagnosed with this type of syndromic condition
(details in Figure 2) were supplied to the model for classifi-
cation, all of which were classified as control, further con-
firming the specificity of this classifier.
Classification of Subjects with an Uncertain Diagnosis of
a Constitutional Syndrome
A common challenge in medical genetics practice involves
case subjects presenting with non-specific clinical features
or carrying a VUS in a potentially clinically relevant gene.
We compiled a total of 67 subjects who, based on clinical
or mutational assessments, had been suspected to have
one of the syndromes noted above (Table S5 and Figure 3).
Our trial utilizing the constructed model revealed that 21
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Figure 2. Concurrent Classification of
Constitutional Syndromes using DNA
Methylation Data
A multi-class SVM classifier generates 16
scores ranging from 0 to 1 for every given
individual (y axes), as the level of confi-
dence for having any of the 16 pheno-
types for which the model is trained for
(x axes). The first 15 classes represent
different syndromes and the last one indi-
cates a state that the DNA methylation
profiling is not indicative of any of the
disorders in the model (healthy control
subjects or other diseases). The figure
shows trials performed for individuals
(represented with hollow points) known
to have one of the constitutional syn-
dromes indicated on the x axes, from
both the training (blue) and testing (red)
cohorts (Table S1). Every panel illustrates
trials for a group of subjects with a
distinct phenotype as indicated on top
of the panel. The first 15 panels show
that every affected subject has received
the highest score in the correct disease
category. Subjects from the testing cohort
(red) have also received scores similar to
those in the training cohort (blue) with
the highest scores in the correct cate-
gories. The last panel represents a total
of 3,307 subjects composed of 2,880
healthy control subjects and 442 case subjects with confirmed diagnoses of constitutional disorders other than those in the model,
including imprinting defect disorders (Angelman syndrome [n ¼ 14], Prader-Willi syndrome [n ¼ 7], Silver-Russell syndrome
[n ¼ 64], and Beckwith-Wiedemann syndrome [n ¼ 9]), Weaver syndrome (n ¼ 7), Saethre-Chotzen syndrome (n ¼ 25), Rett syndrome
(n ¼ 28), Coffin-Lowry syndrome (n ¼ 11), RASopathies (Noonan syndrome [n ¼ 69], cardiofaciocutaneous syndrome [n ¼ 15], and
LEOPARD syndrome [n ¼ 2]), fragile X syndrome (n ¼ 50), and autism spectrum disorders (n ¼ 141). All of these subjects are correctly
classified into the final category. Due to small sample sizes, no testing cohort is available for subjects with ADCADN and GTPTS.
Abbreviations: CdLS, Cornelia de Lange syndrome; CJS, Claes-Jensen syndrome; FHS, Floating-Harbor syndrome; GTPTS, genitopatel-
lar syndrome.
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(31%) of these case subjects showed a methylation profile
consistent with the queried syndromes. In many instances,
this occurred in individuals for whom a causative sequence
variant could not be identified. This included a subject with
a confident clinical assessment for CHARGE syndrome but
no candidate coding sequence variant in CHD7 (MIM:
608892), who was found by our model to have a methyl-
ation profile consistent with CHARGE syndrome; or three
subjects with a clinical consideration of Down syndrome
but with normal CNV microarray testing, one of whom
was classified by our model as Down syndrome resulting
from an apparently mosaic event. The majority of the
assessed case subjects, however, did not have the initially
assumed disorders. Of interest, few of these case subjects
were classified into categories other than their primary
suspected phenotypes, including a 9-year-old male with a
VUS in KDM5C (MIM: 314690, responsible for Claes-Jensen
syndrome) who was classified by our model as Sotos
syndrome; a person referred for assessment of a VUS
in CHD7 (CHARGE syndrome) who was classified as
ADNP syndrome (ADNP-1 subcategory, later confirmed to
carry a frameshift mutation within the ADNP-1 region:
GenBank: NM_015339.2; c.2491_2494del [p.Leu831Ilefs*
82]); and a subject being queried for Kabuki syndrome
who was found to be a case of Claes-Jensen syndrome
(Figure 3). To support these predictions, wherever possible,
secondary clinical and genetic variant assessments were
performed in which the results were found to be in compli-
ance (Table S5).
Screening of Unsolved ND/CA-Affected Individuals for
Constitutional Syndromes
We assessed whether our model can be used to screen for
syndromes with defined epi-signatures in two cohorts
of unresolved subjects with ND/CA presentations (total
n ¼ 965). The first cohort was composed of 476 subjects,
the majority of who had undergone CNV microarray
testing as part of the standard clinical workup along with
additional genetic testing in some instances, including tar-
geted gene/panel or exome sequencing. The second cohort
was, obtained from GEO (GSE89353),9 comprising 489
subjects with both CNV and exome sequencing assess-
ments. These individuals presented with various forms of
ND/CA, including facial dysmorphism, DD/ID, degenera-
tive neural disease, autism, and congenital heart and other
organ defects, though none were suspected of having any
of the syndromes above, or had a causative genetic etiology
identified. Applying our classification model to these sub-
jects identified individuals with DNAmethylation patterns
consistent with ATRX syndrome (n ¼ 1), ADNP syndrome
(n ¼ 2), BAFopathies (n ¼ 2), CdLS (n ¼ 1), CHARGE syn-
drome (n ¼ 1), CJS (n ¼ 1), GTPTS (n ¼ 1), Kabuki
syndrome (n ¼ 4), Sotos syndrome (n ¼ 1), and Williams
syndrome (n ¼ 1, Table S6). Individual examination of
the DNA methylation patterns of the identified case sub-
jects using disease-specific probes was consistent with the
findings (Figure 4). Wherever possible, clinical and molec-
ular assessments were performed to confirm the diagnosis
of these subjects (Table S6). DNA sequencing of the candi-
date genes identified pathogenic variants in a person pre-
dicted to have a BAFopathy (Coffin-Siris syndrome,
ARID1B [MIM: 614556]; GenBank: NM_001346813.1;
c.5271del [p.Lys1718Argfs*48]) and in another classified
as Kabuki syndrome (KMT2D [MIM: 602113]; GenBank:
NM_003482.3; c.13890_13894del [p.Pro4631Ilefs*14]). In
a second subject predicted to have Kabuki syndrome, a
VUS was found two base-pairs upstream of the fourth
exon-intron junction (KMT2D; GenBank: NM_003482.3;
c.509A>G [p.Gln170Arg]). Clinical assessments for all
of these subjects were found to be consistent with the
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Figure 3. Classification of Uncertain
Clinical Case Subjects
The model presented in Figure 2 was used
to assess subjects with uncertain clinical/
molecular diagnoses. The above figure
shows three groups of uncertain case
subjects for at least one of whom in every
category the prediction was found to be
different fromwhat was initially suspected.
The first panel shows 11 subjects suspected
to have CHARGE syndrome, out of which 5
are classified to have CHARGE syndrome
and another 5 are predicted to have none
of the syndromes in the model. The
final subject (shown in red), however, has
received the highest score for the ADNP-1
category and low scores for all others. The
second panel represents trials performed
for those suspected of having Claes-Jensen
syndrome (n ¼ 6) among whom 4 case
subjects of CJS and 1 case subject of Sotos
syndrome (red) were identified. Similarly,
in the last panel, among 26 subjects being
assessed for Kabuki syndrome, 1 case of Claes-Jensen syndrome is found in addition to 8 case subjects with Kabuki syndrome (details
in Table S5). Abbreviations: CdLS, Cornelia de Lange syndrome; CJS, Claes-Jensen syndrome; FHS, Floating-Harbor syndrome; GTPTS,
genitopatellar syndrome.
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predictions, including those for whom a pathogenic
variant was not identified in sequence assessment
(Table S6). The only exception was the subject predicted
to have a methylation profile similar to Williams syn-
drome. This syndrome is caused by contiguous gene dele-
tions at Chr7q11.23 (>1.5 Mb), a segment containing
28 genes, and variable length deletion can result in
phenotypic variations. It is not known which of these
genes has the prominent role in establishing the DNA
methylation profile of this syndrome. Our case was a
19-year-old male with intellectual disability, atrial septal
defect, and dysplastic tricuspid valve without any facial
dysmorphism. He did not present the typical features of
the Williams syndrome including distinct facial features
and connective tissue and endocrine abnormalities. He
also did not have supravalvular aortic stenosis, the typical
congenital heart malformation associated with Williams
syndrome due to the deletion of the elastin gene.44–47
Further assessment is needed to investigate the presence
of a genetic defect within the Chr7q11.23 region.
Detection of Imprinting Defects and Trinucleotide
Repeat Expansion Conditions using DNA Methylation
Data
We have previously demonstrated that Infinium arrays
can be used to detect DNA methylation abnormalities in
imprinting defect disorders.6 Imprinted regions present a
hemi-methylated pattern in healthy individuals, whereas
in the affected persons they show a near complete gain
or loss of methylation. For every unresolved subject, we
investigated genomic segments of R3 consecutive probes
showing an outlier methylation pattern relative to 2,880
healthy control subjects (all of the healthy cohorts used
in various stages of this manuscript). The identified regions
were mapped against the known imprinted loci in hu-
mans. This led to the identification of two subjects with
abnormal hypermethylation in the promoter of SNRPN
(MIM: 182279), an indication of Prader-Willi syndrome
(PWS) as well as one subject with hypomethylation in
the same region, consistent with the diagnosis of Angel-
man syndrome (AS). The latter case subject had originally
Figure 4. Examination of DNA Methylation Profiles in Unresolved Case Subjects
Screening of 965 unresolved ND/CA-affected case subjects using the model presented in Figure 2 identified a total of 15 subjects
(Table S6) as potential cases of 10 of the syndromes in the model. Using the CpG probes specific to every condition, we compared
the DNA methylation profiles of the identified subjects to a few representative diagnosed case subjects and healthy control subjects.
The analysis was done using hierarchical clustering by Ward’s method on Euclidian distance. In every panel above, rows represent
the CpG probes and columns represent the subjects. The heatmap panes indicate the phenotype. Blue, healthy control subjects; green,
individuals with the confirmed diagnosis of the syndromes; red, the candidate subject(s) under assessment. The heatmap color scale
from green to red represents the range of the methylation levels (beta values) between 0 and 1. The analysis indicates that every candi-
date case subject presents a DNA methylation pattern consistent with the predicted phenotype, i.e., ADNP (A), ATRX (B), BAFopathies
(C), CHARGE (D), Cornelia de Lang (E), Claes-Jensen (F), genitopatellar (G), Kabuki (H), Sotos (I), and Williams (J) syndromes.
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been assumed to have Rett syndrome, a known differential
diagnosis of AS, based on the finding of a variant inMeCP2
(MIM: 300005, IVS2-19delT) at age 3 years. However, her
clinical course was different from Rett syndrome when re-
assessed at 18 years, and the updated finding changed her
ultimate clinical diagnosis. Subsequent CNV assessment
confirmed copy number alterations at 15q11.2 in all of
these case subjects. In another individual with global
developmental delay, autism, and ptosis, we identified a
hypomethylated region in the promoter of MKRN3
(MIM: 603856), a maternally imprinted locus located
within the AS/PWS region; however, this person did not
have an abnormal DNA methylation pattern in the pro-
moter of SNRPN. Deletions in the paternal chromosome
15 that do not include MKRN3 have been documented in
PWS, indicating that the loss of imprinting in this gene
is not required for PWS.48 However, a single case subject
with a similar clinical presentation to our subject,
including DD, obesity, mild infantile hemiplegia, facial
dysmorphism, and mild ptosis has been reported in the
literature whose deletion overlaps MKRN3, but similar to
our case subject she did not have PWS or abnormal DNA
methylation in SNURF/SNRPN.48 This suggested the
abnormal imprinting of theMKRN3 promoter as a possible
causative event in our case subject. We also identified a
subject with abnormal hypomethylation in KCNQ1OT1
(MIM: 604115), indicating a diagnosis of Beckwith-Wiede-
mann syndrome, and two subjects with hypomethylation
in the 50 UTR of MEG3 (MIM: 605636), a paternally im-
printed region where the loss of the imprinted allele
is known to cause Temple (MIM: 616222) syndrome
(Table S6, Figure 5).
A different cause of ND/CA that can be identified
through DNA methylation analysis is the DNA methyl-
ation defects associated with the pathological expansion
of trinucleotide repeats.7 In cases where CpG dinucleotides
are part of the repeat element, these expansions can result
in an abnormal methylation pattern in the region and, if
located in the promoter, can also lead to transcription
disruption. We examined genes known to have such path-
ogenic repeat expansions in congenital disorders.50 We
identified three male subjects with excessive hypermethy-
lation of the FMR1 (MIM: 309550) promoter (CGG repeat
expansion, Figure 5). All three had clinical features consis-
tent with a diagnosis of fragile X syndrome (Table S6). Two
of them had been previously assessed by PCR where no
abnormality was detected. Subsequent Southern blotting
confirmed the triplet repeat expansion of the FMR1 pro-
moter in these case subjects. The remaining subject was
not available for molecular re-assessment. In addition, we
Figure 5. Detection of Imprinting De-
fects and Trinucleotide Repeat Expansion
Disorders using DNAMethylation Analysis
The figure shows the DNA methylation
pattern of four imprinted regions (A–D)
and two coordinates with trinucleotide
repeat elements (E and F) in 2,880 healthy
individuals (blue) along with subjects
identified with an imprinting or a trinu-
cleotide repeat disorder (red and green).
The x axis indicates the genomic coordi-
nates and the y axis represents the DNA
methylation levels between 0 and 1.
Circles indicate the DNA methylation
level for every individual at one CpG
site. Neighboring CpG sites are connected
with a line.
(A) Two subjects with hypermethylation
(red) and one subject with hypomethyla-
tion (green) in the promoter of SNRPN are
shown, indicating a deviation from the
normal imprinting pattern (hemi-methyl-
ation) in Prader-Willi and Angelman syn-
dromes, respectively.
(B) An extensive hypomethylation in
the promoter of the imprinted gene
KCNQ1OT1, indicating Beckwith-Wiede-
mann syndrome.
(C) Hypomethylation in the imprinted re-
gion mapping to the promoter of MKRN3.
(D) Hypomethylation of the promoter of
MEG3 in two subjects.
(E) Healthymales and females in the promoter of FMR1 show a hypo- and hemi-methylated pattern (blue), respectively. Three male sub-
jects are shownwith a hemi-methylation pattern (n¼ 1, mosaic event), and a full hypermethylated pattern (n¼ 2), an indication for the
expansion of the CGG repeat beyond the normal count (fragile X syndrome).
(F) Two individuals show increased methylation in the promoter of DIP2B, indicating CGG repeat expansion associated with mental
retardation, FRA12A type. The same increased DNA methylation pattern is also observed in two apparently healthy subjects. Notably,
the extended repeat in this region is not 100% penetrant.49
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found two case subjects with intellectual disability who
had promoter hypermethylation of the DIP2B (MIM:
611379) gene (Figure 5, Table S6), in which the CGG-repeat
expansion has been shown to be associated with the
transcriptional silencing of the brain-expressed gene
DIP2B, resulting in the neurocognitive problems associated
with mental retardation, FRA12A type (MIM: 136630).49
Exploration of Rare DNA Methylation Epi-variants in
Undiagnosed Individuals
As previously demonstrated,9 the presence of ND/CA in
some case subjects can be attributed to highly penetrant
methylation defects at isolated loci across the genome
(epi-variants). Our screening of the epigenome for these
variants among the unresolved case subjects identified
136 rare epi-variants in 109 individuals showing an outlier
methylation pattern compared to 2,880 normal control
subjects (Table S7). The coding genes overlapping or prox-
imal to the identified regions were individually reviewed
for possible clinical associations with the individuals’ clin-
ical presentations (Tables S6 and S7).
Assessment of regions mapping to genes known to cause
Mendelian disorders identified a subject with intellectual
disability and short stature with a hemi-methylation in
the PDE4D (MIM: 600129) promoter (Figure 6A). This
gene is responsible for acrodysostosis (MIM: 614613), char-
acterized by skeletal abnormality and developmental
delay. In the normal population, this gene promoter is al-
ways hyper-methylated, potentially downregulating the
gene. Consistent with this finding, the mechanism of
involvement for PDE4D mutations in acrodysostosis is
proposed to be a gain-of-function effect.51 Given that the
major phenotype of our case subject, i.e., short stature, is
present in nearly all of the case subjects with acrodysosto-
sis, this methylation finding was considered a potential
candidate for this case. In another subject with a progres-
sive neurodegenerative disorder with features including
ataxia, dysarthria, spasticity, dystonia, and brain atrophy,
we identified a gain of methylation in the promoter of
STUB1 (MIM: 607207), a region remaining unmethylated
in the normal control subjects (Figure 6B). Loss-of-func-
tion mutations in STUB1 are associated with autosomal-
recessive spinocerebellar ataxia (MIM: 615768),52 which
virtually matched the clinical presentations of our sub-
ject. In another case subject with neuromuscular symp-
toms, including hypokinesia, spasticity, and dystonia, we
observed a hemi-methylation pattern in the promoter of
NDUFB8 (MIM: 602140), compared to a completely hypo-
methylated status in all of the control subjects. Loss-of-
function mutations in NDUFB8 result in mitochondrial
complex I deficiency (MIM: 618252).53 Follow-up genetic
testing for the evidence of disruption of the second allele
in the context of these recessive disorders and the subjects’
presentations was not performed, but may have further
diagnostic utility in these two latter cases.
The majority of the findings, however, occurred at genes
that have not yet been established to cause a Mendelian
phenotype. This included six individuals with autism
spectrum disorders (ASD) who were identified to have a
promoter hypermethylation in genes previously known
to be downregulated (i.e., PLXNA4 [MIM: 604280] and
RASL10B [MIM: 612128]), to harbor CNV breakpoints
(USP15 [MIM: 604731] and FAM19A2 [MIM: 617496]), to
show CNV amplification (PLCD3 [MIM: 608795]), or to
have de novo mutations reported in other ASD-affected
case subjects (PPP2R1B [MIM: 603113]). We also identified
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Figure 6. Detection of Rare Epi-variants
with Potential Explanation of the Unre-
solved ND/CA-Affected Case Subjects’
Phenotypes
The figure shows the DNA methylation
pattern of 4 selected rare epi-variants that
are likely explanatory of the phenotypes
observed in 6 subjects (red) compared
with 2,880 healthy individuals (blue).
The x axis represents the genomic coordi-
nates and the y axis shows the DNA
methylation levels between 0 and 1. Cir-
cles indicate the DNA methylation level
for every individual at one CpG site.
Neighboring CpG sites are connected
with a line.
(A) Hypomethylation in the promoter of
PDE4D.
(B) Hypermethylation in the tightly unme-
thylated promoter of STUB1.
(C) Three individuals showing a hemi-
methylation pattern in the normally hy-
permethylated promoter of CDC186.
(D) Hypermethylation in the promoter of
ELFN1.
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three unrelated individuals with various presentations of
developmental delay and autism, all of whom displayed
an extensive hemi-methylation in the promoter of
CCDC186, a region fully hypermethylated in the healthy
population (Figure 6C). A nonsense mutation in this
gene (GenBank: NM_018017; c.610C>T [p.Gln204*]) has
previously been reported in a case subject with DD/ID,54
suggesting that the observed event may be involved in
their clinical presentations. We also identified a hemi-
methylation pattern in the gene body of MAD1L (MIM:
602686) in two individuals with ID, which is fully methyl-
ated in the normal population. Partial CNV deletions
encompassing MAD1L are reported in case subjects with
DD/ID and congenital abnormalities.55 Despite recur-
rences in these subjects, these events were not observed
within the 2,880 healthy individuals. Other identified
regions that provided an area for exploration of disease eti-
ology included epi-variants in candidate genes for ID
(MTA1 [MIM: 603526]),56 neurodevelopmental disorders
(PTPRN2 [MIM: 601698]),57 and neural developments
and ID (PTPRO [MIM: 600579]),58 as well as a hypermethy-
lation event in an individual with seizures and ID in the
ELFN1 (MIM: 614964) promoter (Figure 6D), a gene whose
knock-out in mice induces seizures and ID.59 Finally, in an
11-year-old female with DD and seizures, for whom CNV
microarray testing had reported a single copy deletion
(113 kb) of uncertain clinical significance in Chr2p16.1,
we identified a hemi-methylation status 30 kb down-
stream of the deleted segment, at which coordinates all
controls were hypomethylated (Figure 7). This region is an-
notated to the promoter of VRK2 (MIM: 602162), a gene
expressed in the brain in all stages of life, whose variants
have been repeatedly identified in genome-wide associa-
tion studies to be associated with idiopathic generalized ep-
ilepsy, as well as other neurological disorders.60 Consistent
with the hypermethylation event observed here, VRK2 has
been found to be downregulated in the blood of individ-
uals with epilepsy as well as in those with schizophrenia,
bipolar disorder, and multiple sclerosis.61,62 Our finding
provided a functional measure for clinical interpretation
of a CNV change of unknown clinical significance. Further
descriptions of the clinically significant epi-variants and
the clinical/molecular assessment findings of the carrying
unresolved case subjects are provided in Table S6.
Discussion
The clinical genetic testing of developmental delay, intel-
lectual disability and congenital anomalies (ND/CA) began
with clinical karyotyping in the late 1950s. Since then, the
evolution of cytogenetic technologies including the advent
of Giemsa banding, in situ hybridization, and microarrays
continually increased the diagnostic yield of ND/CA.63
In 2010, a consensus statement was issued to consider
clinical copy number testing using microarray as the
first-tier clinical test in individuals with ND/CA, since it re-
sulted in a higher diagnostic rate (15%–20%) compared to
G-banded karyotyping alone (3%–5%).64 The introduction
of clinical genome and targeted gene panel sequencing in
the past decade has resulted in further improvement in
the cumulative diagnostic yield to 42%–62%.3 However,
these assays suffer from several limitations. Targeted ap-
proaches such as gene panel sequencing are a powerful
tool for rule-out assessments, but their utility in screening
is limited to a set of specific genes. Genomic approaches
including exome and genome sequencing and cytogenetic
microarray analysis enable the screening of broader clinical
genetic etiologies; yet, they suffer from analytical sensi-
tivity for all types of genetic variations (screening as
opposed to rule-out testing). Both of these approaches
suffer from limitations in the interpretability of the de-
tected genetic variants (i.e., VUSs), restricted knowledge
in the genetic etiology of a significant proportion of clinical
conditions, and technical limitations in the detection of
complex or balanced genomic rearrangements. As a result,
a substantial proportion of case subjects with ND/CA still
remain unsolved.
In this study, we have shown that genomic DNA
methylation analysis can be used to assign a diagnosis to
Layered H3K27Ac 
CNV 
Figure 7. Hypermethylation of the VRK2 Promoter Secondary to
a 30 kb Upstream Deletion
The figure shows a hemi-methylation pattern in a tightly unme-
thylated CpG island in the promoter of VRK2, secondary to a mi-
crodeletion 30 kb upstream. The deleted element is shown to
harbor a site enriched for Histone 3 lysine 27 acetylation
(H3K27ac), a marker of active regulatory elements. Affected case
subjects, red; 2,880 healthy individuals, blue; x axis, genomic co-
ordinate; y axis, DNA methylation levels between 0 and 1; circles,
DNA methylation level for every individual at one CpG site.
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a significant subset of individuals with ND/CA, who may
not be identifiable through conventional approaches
(Tables S5 and S6). The accumulating reports of DNA
methylation epi-signatures in the peripheral blood of
constitutional disorders provide grounds for the develop-
ment of novel methods for clinical screening and assess-
ment. Our results indicate that unresolved ND/CA-affected
subjects could have a wide range of conditions, from those
relatively common and well-characterized such as Down
syndrome to others that are rarer and difficult to recognize
clinically such as Coffin-Siris syndrome. Overlapping
clinical features with other conditions and non-specific
presentations limit the clinical detection of these syn-
dromes. In a large proportion of these cases, sequence anal-
ysis does not provide a conclusive result. In 30%–40% of
individuals presenting with Coffin-Siris and Kabuki syn-
dromes, for instance, a causative variant is not identified
(see GeneReviews in Web Resources).65 While some of
these case subjects might havemutations in yet-to-be iden-
tified genes, others carry VUSs or variants not sequenced in
routine screening, such as large indels or noncoding
variants. In some other situations, the routine methods
are not sensitive enough in the detection of a mosaic caus-
ative event as noticed in a subject with Down syndrome
and another one with fragile X syndrome here. In the
case of imprinting disorders, CNV analysis cannot detect
a portion of the defects since some of them are caused by
an aberrant establishment of imprinting with a normal
allelic balance in the region. We demonstrated that DNA
methylation profiling provides a powerful solution to these
challenges. Our study shows that syndrome-specific DNA
methylation epi-signatures can be reliably utilized to
resolve ambiguous clinical case subjects, to reclassify those
presenting with VUS, to re-assign novel diagnoses for
whom the initial clinical assumption is not correct, and
to identify cases of a disease through screening of an unre-
solved population with ND/CA.
In addition to disorders with well-defined DNA methyl-
ation signatures, we have also identified rare gene-specific
epi-variants among the unresolved ND/CA-affected popu-
lation (Table S6). These included the relatively common
imprinting and trinucleotide repeat expansion disorders,
as well as rare and previously unreported epi-variants,
some of which overlapped genes with a biological/clinical
relevance to the individuals’ clinical presentations. How-
ever, the majority of the rare epi-variants that we found
were not clinically interpretable as they either occurred
at genes with no known function related to the disease
or in intragenic regions. Our evaluation of the epi-variants
was therefore restricted to those occurring at the gene pro-
moters, assuming an inverse association between the gene
expression and promoter methylation. It is acknowledged
that DNA methylation changes can alter gene expressions
through other mechanisms. Gene body methylation
changes are proposed to have a direct association with
gene expression. Hypermethylation of the repetitive ele-
ments in non-genic regions is known to have a role in
the stability of the genome and silencing of transposons,
the abnormal regulation of which can disrupt the function
of other genes. DNA methylation alterations at regulatory
elements such as those in enhancers and transcription fac-
tor binding sites can theoretically influence the expression
of genes both in cis and trans. However, currently, the
above-mentioned mechanisms are challenging to investi-
gate in a clinical setting due to the lack of information
on the functional consequence of a methylation change
in non-promoter regions.
Adaptation of epi-variant assessment in disease
screening would require building clinical databases of
epi-variants observed in ND/CAs and consensus guidelines
for their interpretation, similar to what is currently avail-
able for sequence variants and CNVs. In addition, func-
tional genomic studies would be required to reveal the
consequence of epi-variants on the genes whose promoter
is not influenced by the event but have the potential to be
affected in trans. Population epigenome projects can reveal
genomic coordinates tightly regulated across the healthy
population (i.e., a reference epigenome), pinpointing
the genomic regions that are less tolerant of epigenetic
variations. Construction of consensus guidelines for inter-
pretation of epi-variants would proceed following the
completion of these steps and particularly after the
conduct of clinical trials to evaluate cost-effectiveness,
feasibility, and diagnostic yield of epigenomic testing in
constitutional disorders. Engagement of the American Col-
lege of Medical Genetics and Genomics (ACMG) and the
Association for Molecular Pathology (AMP) would be
required for the development and standardization of clin-
ical and laboratory guidelines for clinical epigenomic
testing. Identified epi-variants may be further investigated
based on the allelic involvement, effects on the gene
expression, and mode of inheritance. Finally, unlike epi-
signatures that due to the genome-wide distribution of
their CpG sites are less likely to be fully affected by tech-
nical problems, epi-variants warrant technical validations
using orthogonal assays before reporting.
Adaptation of epi-signature assessment in the clinical
setting, however, would require a different set of consider-
ations. Epi-signatures are composed of a combination of
DNA methylation changes across multiple loci, mapping
and utilizing whichmight require compilation of reference
methylation databases of diagnosed cases and healthy
controls and development of computational tools. Clinical
laboratories may choose to participate in lager laboratory
networks with shared reference databases and bioinformat-
ics resources similar to the current noninvasive prenatal
testing (NIPT) model, or by generating data on-site and
accessing centralized bioinformatics and database facilities.
It will be important to ensure that such clinical diagnostic
services meet performance indicators, which may involve
adaptation of proficiency testing models possibly through
the College of American Pathologists (CAP). Identification
of an epi-signature as part of a clinical screen may warrant
development of guidelines for subsequent confirmatory
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targeted genetic testing as well as guidelines for the use of
epi-signatures for re-classification of genetic VUSs. Recog-
nizing that there will be individuals with disorder-specific
epi-signatures but with no identifiable genetic variation
in the known disease-related genes, the establishment of
genetic diagnosis in the absence of sequence findings will
warrant further investigations.
A current limitation of this assay to consider is that it is
designed for peripheral blood. It is possible that some dis-
orders do not exhibit epi-signatures or epi-variants in
blood. Also, germ-line mosaicism restricted to tissues other
than peripheral blood may decrease the clinical sensitivity
of this technology in some cases. Further investigations
and development of reference datasets in other accessible
tissue types such as buccal epithelium or fibroblasts will
be needed to extend the utility of this assay from periph-
eral blood to other tissues.
This study demonstrates that genome-wide DNA
methylation testing can be successfully applied to enable
molecular diagnosis of genetically unresolved ND/CA-
affected case subjects. We propose that genomic DNA
methylation assessment has a clinical utility in a broad
range of constitutional disorders. The present technical
cost of a genomic DNA methylation experiment is com-
parable to the cost of individual tests currently in use
for the detection of imprinting or trinucleotide repeat
expansion disorders. Both of these procedures could be
replaced at a competitive cost by epigenomic analysis, a
single test that provides much more information
regarding the underlying genetic etiology of ND/CA. As
more syndromes are being mapped for DNA methylation
epi-signatures and more clinical DNA methylation data
are becoming available for interpretation of rare epi-vari-
ants, epigenomic testing is expanding the potentials to
significantly improve the current diagnostic yield of the
ND/CA.
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